📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. (2023)

First Author: Charles-Schoeman C

Attributed to: The 'CARDIOvascular-Immune-Mediated Inflammatory Diseases (CARDIO-IMID) UK Network' funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/ard-2022-222259

PubMed Identifier: 36137735

Publication URI: http://europepmc.org/abstract/MED/36137735

Type: Journal Article/Review

Volume: 82

Parent Publication: Annals of the rheumatic diseases

Issue: 1

ISSN: 0003-4967